Rotterdam, October 10th, 2017 – Dutch medical start-up FABPulous B.V. welcomed a new round of investment on Tuesday led by Dutch Life Science Venture fund Swanbridge Capital that
MAASTRICHT, Oct 16, 2017 – The EASME at the European Commission nominated FABPulous BV’s founder Jan Glatz and Ger Biesbrouck of Medavinci Development, Amsterdam on Monday for the
Maastricht, Netherlands, May 3, 2017 – Dutch point of care diagnostics solution company FABPulous BV won new patents across the European Union on Wednesday for the unique Integrated
The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its
Following successful completion of the €2.2m Series B funding round, FABPulous BV reorganises roles within an enlarged management team to meet the challenges of evolution from R&D start
FABPulous BV closes Series B Funding; Begins commercial activities with rapid 5-minute point-of-care IVD for myocardial infarction based on H-FABP February 4th 2015; Maastricht – Today FABPulous B.V.
FABPulous was delighted to be notified in December 2014 that it would be awarded an exceptional 100% contribution grant for €1.63m to fund clinical trials for use of